Upload File

oncoletter 2017/0… · durvalumab + tremelimumab vs durvalumab vs tremelimumab in i-icc arm +...

  • Home
  • Documents
  • oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
32

Upload: others

Post on 20-Jul-2020

4 views

Category:

Documents


0 download

Report

TRANSCRIPT

Page 1: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 2: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 3: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 4: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 5: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 6: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 7: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 8: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 9: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 10: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 11: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 12: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 13: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 14: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 15: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 16: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 17: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 18: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 19: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 20: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 21: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 22: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 23: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 24: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 25: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 26: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 27: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 28: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 29: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 30: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 31: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal
Page 32: oncoletter 2017/0… · Durvalumab + Tremelimumab vs Durvalumab vs Tremelimumab in I-ICC Arm + (n=36; 12 subjoctstviral status typo) ... ASCO 2016. Abstract 4012. 2017 Gastrointestinal

III SESSIONE Highlights in Immunoncologia Il NSCLCmedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/20171013ME_32... · cells, suggest that durvalumab may be an effective adjuvant

Overview of and current indications for the use of immune ...images.researchtopractice.com/2017/Meetings/...Galsky et al. ESMO 2016 Sharma, et al. Lancet Oncology 2017. Durvalumab

Immunotherapy in Patients with Non-Small Cell Lung Cancer · Tremelimumab Human IgG2 Phase 3 PD‐1 Nivolumab Human IgG4 MEL, NSCLC, RCC Pembrolizumab Humanized IgG4 MEL, PD‐L1

CALLA: Efficacy and safety of concurrent and adjuvant … · CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone

f6publishing.blob.core.windows.net · Web viewA randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable

9002: Durvalumab ± tremelimumab + platinum- etoposide in first … · 2020-06-18 · AEs assessed by the investigator as possibly related to any study treatment. ... – Benefit

Safety and Clinical Activity of Durvalumab Monotherapy in ... · H. Lee Moffitt Cancer Center, Tampa, FL, USA; 7. ... Ontario, Canada; 8. Earle A. Chiles Research Institute, Providence

DURVALUMAB IN STAGE III NSCLC · 2020-01-04 · LUNG CANCER • Approximately 234,000 patients annually • Frequency decreasing • Leading cause of cancer‐related mortality in

Olaparib and durvalumab in patients with germline BRCA ... · Web viewoccur in approximately 5% of breast cancer patients1,2 and are associated with high risk of cancer.3 BRCA proteins

oncoletter · Cabozantinib TKI targeting VEGF receptors, MET, AXL, RET Improves PFS in advanced renal cell carcinoma in 1st line (vs. sunitinib)l and in 2nd line (vs. everolimus)

Combinations in Cancer Immunotherapy - Roche2a47d70f-f2b9-4871-a285-7353a9522… · Combinations in Cancer Immunotherapy ... 5 uncertainties in the discovery, ... Durva+AZD4547 Durva+tremelimumab

AstraZeneca Pharmaceuticals LP IMFINZI- durvalumab

CLINICAL PROTOCOL TREMELIMUMAB (CP-675,206) IN …

SABCS 2016 - oncoletter€¦ · Rebecca Roy ance, Adam Shaw, Ian Smith, Rose Thompson, Kirsten Timms, Andrew Wardley, Gregory W son, Mark Harries, Paul Ellis, Alan Ashworth, James

CONSENSUS OR CONTROVERSY?images.researchtopractice.com/2017/Meetings/... · Avelumab:ALK inhibitor (crizotinib and lorlatinib), anti-41BB, anti-OX40 ... tremelimumab 1 mg/kg Durvalumab

Pre0120-Greystoke Alastair · Pembrolizumab(MK-3475) Keytruda PD-1 MSD Atezolizumab (MPDL3280A) Tecentriq PD-L1 Roche Durvalumab(MEDI4736) Imfinzi PD-L1 AstraZeneca/Celgene ... Data

SABCS 2018 - oncoletter€¦ · committee member for the IMpassion130 and KATE2 trials This study is sponsored by F. Hoffmann-La Roche, Ltd Editorial support, funded by the sponsor,

Immune checkpoints - Clinical use€¦ · IgG4 PEMBROLIZUMAB ATEZOLIZUMAB DURVALUMAB ... (not IgE) Causes Anyallergen Drugs Manifestations Skin rash, dyspnea, nausea/vomiting, hypotension

SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

oncoletter€¦ · P662 Do Patients with Relapsed/Refractory Multiple Myeloma Benefit From Early Treatment at Biological Relapse? Carlos Fernández de Larreal, Fernando Escalante2,

Rosario García Campelo Servicio de Oncología Médica · NSCLC (2016) *With docetaxel, paclitaxel, gemcitabine, nab-paclitaxel, vinorelbine. ... Tremelimumab Anti-PDL1/PD1 ... Herbst

Patient-reported outcomes with first-line durvalumab plus

2392 Case Report Durvalumab monotherapy as a third-line

Faculty - Amazon S3€¦ · >2 Ventana SP142 Complementary Benchmark Ultra >50% TC, >10% IC Durvalumab (Imfinzi) − Venana ... assays by Roche Ventana use only on Ventana-automated

Mogamulizumab in Combination with Durvalumab or ... · 6/25/2020  · 1 Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: a Phase

Sia Daneshmand, M.D.images.researchtopractice.com/2017/Meetings/RTPLive/12...this month of 2 other PD-L1 inhibitors, avelumaband durvalumab. USC Institute of Urology Conclusions •

IMFINZI (durvalumab) Access & Reimbursement Guide€¦ · Helping Patients Access The Care They Need For assistance please call your AstraZeneca Access 360™ Reimbursement Counselor

761069Orig1s000 - Food and Drug Administration · 761069Orig1s000 PHARMACOLOGY REVIEW(S) MEMORANDUM Imfinzi (durvalumab) Date: March 16, 2017 To:File for BLA 761069 ... Project Manager:

Immunotherapeutic Approaches in the Treatment of NSCLC · Durvalumab [Rizvi ASCO 2015 Abst 8032] Phase 1, dose-escalation, cohort expansion: Any. Any ≥25% tumor cells staining at

ResponsetoImmuneCheckpointInhibitioninTwo Patients with ...€¦ · residual irAE, the patient was retreated with durvalumab from March 22, 2016, until May 31, 2016, completing the

Immunotherapy for Lung Cancer · –Pembrolizumab (Keytruda) •PD-L1 –Atezolizumab (Tecentriq) –Durvalumab (Imfinzi) –Avelumab (Bavencio) 2017 Community Cancer Care Educational

pbs.gov.aupbs.gov.au/.../files/durvalumab-psd-november-2018.docx · Web viewAPF12/APF18= proportion of patients alive and progression-free at 12/18 months from randomisation; DOR=duration

2L Advanced Urothelial Carcinoma: New Options and Sequencing · 21,1 15 19,6 17,8 18,2 10,3 9 8,7 18,2 13,7 0 5 10 15 20 25 Pembrolizumab Atezolizumab Nivolumab Durvalumab Avelumab

News Briefing: Highlights from the 2018 Multidisciplinary ......EAGLE trial (NCT02369874) will assess the combination of durvalumab + tremelimumab and durvalumab monotherapy compared

CP.PHAR.339 Durvalumab (Imfinzi) · by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable. The purpose of this clinical policy is to provide